Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: A possible role for dietary peptides

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 289, Issue 3 58-3, 2005, Pages

  Aziz, Alfred ^a   Anderson, G Harvey ^a   Giacca, Adria ^a   Cho, France ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Amino acids; Glucagon like peptide 1; Gut; Hormones

Indexed keywords

ALBUMIN; AMINO ACID; BRANCHED CHAIN AMINO ACID; EXENDIN 4; FATTY ACID; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCEROL; INSULIN; LEPTIN; PHOSPHATE BUFFERED SALINE; PROTEIN HYDROLYSATE; TYROSINE; WATER;

AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIGESTION; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPERGLYCEMIA; INGESTION; MALE; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTAKE; RAT; VENOUS BLOOD; WHEY;

AMINO ACIDS; ANIMALS; BLOOD GLUCOSE; DIETARY PROTEINS; DRUG COMBINATIONS; HYPERGLYCEMIA; INJECTIONS, INTRAPERITONEAL; MALE; OSMOLAR CONCENTRATION; PEPTIDES; PROTEIN HYDROLYSATES; RATS; RATS, WISTAR; RECEPTORS, GLUCAGON; VENOMS;

EID: 23944515974     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00850.2004     Document Type: Article

References (42)

1. Anderson GH. Control of protein and energy intake: role of plasma amino acids and brain neurotransmitters. Can J Physiol Pharmacol 57: 1043-1057, 1979.
2. Anderson JW, Konz EC, and Jenkins DJ. Health advantages and disadvantages of weight-reducing diets: a computer analysis and critical review. J Am Coll Nutr 19: 578-590, 2000.
3. Appel NM, Track NS, and Van Loon GR. Autonomic and endocrine participation in opioid peptide-induced hyperglycemia. J Anton Nerv Syst 20: 221-231, 1987.
4. Aziz A and Anderson GH. Exendin-4, a GLP-1 receptor agonist, modulates the effect of macronutrients on food intake by rats. J Nutr 132: 990-995, 2002.
5. Aziz A and Anderson GH. Exendin-4. a GLP-1 receptor agonist, interacts with proteins and their products of digestion to suppress food intake in rats. J Nutr 133: 2326-2330, 2003.
6. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes III: 121-124, 2003.
7. Cammisotto PG, Gelinas Y, Deshaies Y, and Bukowiecki LJ. Regulation of leptin secretion from white adipocytcs by norepinephrine and fatty acids. Diabetologia 46: A225-A225, 2003.
8. Choi YH, Chang N, and Anderson GH. An intragastric amino acid mixture influences extracellular amino acid profiles in the lateral hypothalamic area of freely moving rats. Clin J Physiol Pharmacol 77: 827-834, 1999.
9. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122: 531-544, 2002.
10. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, and Bloom SR. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281: E155-E161, 2001.
11. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Yarns A, Kim D, and Baron AD. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26: 2370-2377, 2003.
12. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szaparv PO, Rader DJ, Edman JS, and Klein S. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 348: 2082-2090, 2003.
13. Froetschel MA, Azain MJ, Edwards GL, Barb CR, and Amos HE. Opioid and cholecystokinin antagonists alleviate gastric inhibition of food intake by premeal loads of casein in meal-fed rats. J Nutr 131: 3270-3276. 2001.
14. Fukui K, Kojima M, Tachibana N, Kohno M, Takamatsu K, Hirotsuka M, and Kito M. Effects of soybean beta-conglycinin on hepatic lipid metabolism and fecal lipid excretion in normal adult rats, Biosci Biotechnol Biochem 68: 1153-1155, 2004.
15. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, and Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Client 268: 19650-19655, 1993.
16. Grouzmann E, Cavadas C, Grand D, Moratel M, Aubert JF, Brunner HR, and Mazzolai L. Blood sampling methodology is crucial for precise measurement of plasma catecholamines concentrations in mice. Pflügers Arch 447: 254-258, 2003.
17. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, and Goke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117-126, 1995.
18. Johnson MD, Schier DN, and Barger AC. Circulating catecholamines and control of plasma rennin activity in conscious dogs. Am J Physiol Heart Circ Physiol 236: H463-H470, 1979.
19. Kieffer TJ, McIntosh CH, and Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596, 1995.
20. Kitts DO and Weiler K. Bioactive proleins und peptides from food sources. Applications of bioproccsscs used in isolation and recovery. Curr Pharm Des 9: 1309-1323, 2003.
21. Kolterman OC, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, and Baron AD. Synthetic exendin-4 (exenutide) significantly reduces postprandial and lasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88: 3082-3089, 2003.
22. Lam TK, Yoshii H, Haber CA, Bogdanovic E, Lam L, Fantus IC, and Giacca A. Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab 283: E682-E691, 2002.
23. Malendowicz LK, Nowak KW, Zyterska A, Mussdorfer CC, Macchi C, and Nowak M. Exendin-4, a GLP-1 receptor agonist, stimulates entero-insular axis in the rat, through a mechanism involving adrenal medulla. Biomed Res (Tokyo) 22: 295-297, 2001.
24. Meisel H. Biochemical properties of regulatory peptides derived from milk proteins. Biopolymers 43: 119-128, 1997.
25. Morita K, Teraoka K, Oka M, and Haniano S. Further studies on the relationship between tyrosine supply and catecholaminc production in cultured adrenal chromaffin cells. Neurochem Int 20: 229-235, 1992.
26. Navegantes LC, Migliorini RH, and do Carmo Kettelhut I. Adrenergic control of protein metabolism in skeletal muscle. Curr Opin Clin Nutr Metab Care 5: 281-286, 2002.
27. Nishi T, Hara H, Asano K, and Tomita F. The soybean beta-conglycinin beta 51-63 fragment suppresses appetite by stimulating cholecystokinin release in rats. J Nutr 133: 2537-2542, 2003.
28. Parkes O, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, Chen K, and Young A. Pharmucokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev RES 53: 260-267, 2001.
29. Pavlovic M, Wroblewski K, Manevich Y, Kim S, and Biaglow JE. The importance of choice of anaesthetics in studying radiation effects in the 9L rat glioma. Br J Cancer Suppl 27: S222-S225, 1996.
30. Pedersen NL, Nagain-Domaine C, Mahe S, Chariot J, Roze C, and Tome D. Caseinomacropeptide specifically stimulates exocrine pancreatic secretion in the anesthetized rat. Peptides 21: 1527-1535, 2000.
31. Pupovac J and Anderson GH. Dietary peptides induce satiety via cholecystokinin-A and peripheral opioid receptors in rats. J Nutr 132: 2775-2780, 2002.
32. Rayner DV and Trayhurn P. Regulation of leptin production: sympathetic nervous system interactions. J Mol Med 79: 8-20, 2001.
33. Reeves PG, Nielsen FH, and Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123: 1939-1951, 1993.
34. Reyes Toso CF, Linares LM, and Rodriguez RR. Blood sugar concentrations during ketamine or pentobarbitone anesthesia in rats with or without alpha and beta adrenergic blockade. Medicina (B Aires) 55: 311-316, 1995.
35. Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J, Williams T, Williams M, Gracely E.I, and Stern L. A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 348: 2074-2081, 2003.
36. Thorens B, Porret A, Buhler L, Deng SP, Morel P, and Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682, 1993.
37. Vranic M, Miles P, Rastogi K, Yamatani K, Shi Z, Lickley L, and Hetenyi G Jr. Effect of stress on glucoregulation in physiology and diabetes. Adv Exp Med Biol 291: 161-183, 1991.
38. Wolever TM. How important is prediction of glycemic responses? Diabetes. Care 12: 591-593, 1989.
39. Wurtman RJ, Hefti F, and Melamed F. Precursor control of neurotransmitter synthesis. Pharmacol Rev 32: 315-335, 1980.
40. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, and Elmquist JK. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23: 2939-2946, 2003.
41. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez, ME, Hollenbcrg AN, Baggio L, Saper CB, Drucker DJ, and Elmquist JK. Glucagon-like peptidc-1 receptor stimulation increases blood pressure and heart rale and activates autonomic regulatory neurons. J Clin Invest 110: 43-52, 2002.
42. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, and Denaro M. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48: 1026-1034, 1999.